UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000019843
Receipt number R000018715
Scientific Title Carboplatin plus nab-Paclitaxel versus docetaxel for elderly squamous non-small cell lung cancer (CAPITAL study)
Date of disclosure of the study information 2015/11/20
Last modified on 2020/11/24 08:51:38

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Carboplatin plus nab-Paclitaxel versus docetaxel for elderly squamous non-small cell lung cancer
(CAPITAL study)

Acronym

CBDCA+nab-PTX vs DOC for eldery Sq NSCLC Phase III study

Scientific Title

Carboplatin plus nab-Paclitaxel versus docetaxel for elderly squamous non-small cell lung cancer
(CAPITAL study)

Scientific Title:Acronym

CBDCA+nab-PTX vs DOC for eldery Sq NSCLC Phase III study

Region

Japan


Condition

Condition

Eldery patients with advanced squamous non-small-cell lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To compare the efficacy and safety of nab-paclitaxel/carboplatin with docetaxel for eldery patients with advanced squamous non-small-cell lung cancer

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase III


Assessment

Primary outcomes

Overall survival

Key secondary outcomes

Progression-free survival, response rate, toxicity, quality of life


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

A: Docetaxel (60 mg/m2) given on day 1 every 3 weeks until disease progression.

Interventions/Control_2

B: Carboplatin (AUC 6) given on day1 plus nab-paclitaxel (100 mg/m2) given on day 1, 8, 15 every 3 weeks until disease progression.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

70 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Histologically or cytologically confirmed advanced squamous non-small-cell lung cancer
2) Clinical stage IIIB (not amenable to curative radiation), IV or recurrent disease
3) Regardless of the presence of measurable lesions
4) 70 years of age or older
5) Performamne status of 0 or 1
6) Adequate organ funcion
7) life expectancy 12 weeks or more at day1
8) Written informed consent

Key exclusion criteria

1) symptomatic central nervous system metastases
2) A past hypersensitive for polysorbate or albmin
3) peripheral neuropathy CTCAE Grade 2 or more
4) uncontrolled pericardial or pleural effusion or ascites
5) prior palliative radiotherapy for metastatic lesion within 14 days before registration
6) Synchronous or metachronous active double malignancies
7) Infectious disease requiring systemic treatment or severe complications
8) do not consent to contraception
9) Positive for HBs antigen
10) positive for HBs antibody or HBc antibody, and positive for HBV-DNA
11) patients who have been judged by the invedtigator to be inappropriate in this clinical trial for other reasons

Target sample size

250


Research contact person

Name of lead principal investigator

1st name Akihiko
Middle name
Last name Gemma

Organization

Graduate School of Medicine,Nippon Medical School

Division name

Department of Pulmonary Medicine and Oncology

Zip code

113-8602

Address

1-1-5 Sendagi Bunkyoku Tokyo,Japan

TEL

03-3822-8575

Email

agemma@nms.ac.jp


Public contact

Name of contact person

1st name Yutaka
Middle name
Last name Ito

Organization

National Hospital Organization Nagoya Medical Center

Division name

Department of Clinical Research Management, Clinical Research Center

Zip code

460-0001

Address

4-1-1 Sannomaru Nakaku Nagoya, Aichi, Japan

TEL

052-951-1111

Homepage URL


Email

capital.office@nnh.go.jp


Sponsor or person

Institute

National Hospital Organization Nagoya Medical Center

Institute

Department

Personal name



Funding Source

Organization

TAIHO PHARMACEUTICAL CO.,LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

JAPAN


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Hospital Organization Nagoya Medical Center

Address

4-1-1 Sannomaru Nakaku Nagoya, Aichi, Japan

Tel

052-951-1111

Email

capital.office@nnh.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 11 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 12 Month 01 Day

Date of IRB

2015 Year 12 Month 01 Day

Anticipated trial start date

2015 Year 12 Month 01 Day

Last follow-up date

2020 Year 10 Month 31 Day

Date of closure to data entry

2020 Year 12 Month 10 Day

Date trial data considered complete

2021 Year 01 Month 15 Day

Date analysis concluded

2021 Year 06 Month 30 Day


Other

Other related information



Management information

Registered date

2015 Year 11 Month 18 Day

Last modified on

2020 Year 11 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018715


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name